Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study - Top-Institutions - MDSpire

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

  • By

  • Carlyn Rose Tan

  • Sireesha Asoori

  • Chiung-Yu Huang

  • Larissa Brunaldi

  • Rakesh Popat

  • Efstathios Kastritis

  • Joaquin Martinez-Lopez

  • Radhika Bansal

  • Andre De Menezes Silva Corraes

  • Saurabh Chhabra

  • Ricardo Parrondo

  • Sikander Ailawadhi

  • Despina Fotiou

  • Meletios A. Dimopoulos

  • Kwee Yong

  • Catriona Mactier

  • Chris Lau

  • Magdalena Corona

  • Adolfo Jesús Sáez Marin

  • Hira Mian

  • Brian GM. Durie

  • Saad Z. Usmani

  • Thomas G. Martin

  • Yi Lin

  • April 3, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #4

    University of Texas MD Anderson Cancer Center
    University of Texas MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

  • #5

    University College London Hospitals (UCLH)
    University College London Hospitals (UCLH)

    London, England

    Key Differentiators

    • Hematology
    • Oncology
    • Immunotherapy

Original Source(s)

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study

  • by Carlyn Rose Tan, Sireesha Asoori, Chiung-Yu Huang, Larissa Brunaldi, Rakesh Popat, Efstathios Kastritis, Joaquin Martinez-Lopez, Radhika Bansal, Andre De Menezes Silva Corraes, Saurabh Chhabra, Ricardo Parrondo, Sikander Ailawadhi, Despina Fotiou, Meletios A. Dimopoulos, Kwee Yong, Catriona Mactier, Chris Lau, Magdalena Corona, Adolfo Jesús Sáez Marin, Hira Mian, Brian GM. Durie, Saad Z. Usmani, Thomas G. Martin, Yi Lin

  • April 3, 2025

Related Content

Patient Awareness, Attitudes, and Preventive Practices Related to Venous Thromboembolism in Multiple Myeloma: A Cross-Sectional Analysis

Advancing CAR-T therapy in multiple myeloma: a critical appraisal of CARTITUDE-4 and the path toward earlier lines

Romiplostim N01 Enhances Platelet Recovery in Autologous Stem Cell Transplantation with Non-Cryopreserved Peripheral Blood Stem Cells for Plasma Cell Disorders